The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy

Subcutaneous injection of 160 mg is administered once a week.

Induction therapy period (3 months)：Eligible subjects receive induction treatment with Methylprednisone 0.5 g i. v. for 3 consecutive day and followed by orally administration of prednisone at an initial dose of 0.8 mg/kg/day, tapered gradually after 2 months (reduced by 5 mg every 2 weeks) Grouped treatment period (6 months): The maintenance induction treatment regimen is continued, with regular tapering (reducing by 5 mg every 2 weeks) until discontinuation.

An intravenous injection of 0.4 g is administered twice a month.